USPTO serial 88318383
RANDOX DISCOVERY
Reviewed by CopyMark Law Group
Reg. 6203127Status 700
- Filing date
- Status date
- Registration date
- Nov 24, 2020
- Examiner
- CIURPITA, DREW PETER FISHER
- Law office
- PETITIONS OFFICE
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with RANDOX DISCOVERY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Daniel Frohling
Daniel Frohling LOEB & LOEB LLP321 North Clark StreetSuite 2300Chicago, IL 60654Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Diagnostic preparations for scientific purposes; chemical reagents for scientific or medical research and for use in the analysis of food products; enzymes for use in scientific and medical research applications; protein arrays for use in scientific and medical research applications; diagnostic preparations for analysis of food products and water for scientific or research use; clinical diagnostic preparations for clinical or medical laboratory use; clinical diagnostic reagents for in vitro use for clinical or medical laboratory use; chemical reagents other than for medical or veterinary purposes, namely, chemical reagents for detection and monitoring of disease states in vitro for laboratory research purposes; diagnostic proteins, namely, protein arrays for scientific and medical research featuring antibodies and antigens used for monitoring of disease states in vitro | ACTIVE | — |
| 005 | Diagnostic preparations and substances for medical and veterinary purposes; diagnostic kits in the nature of clinical chemistry and immunology test kits for medical use in the detection and monitoring of disease states in vitro, namely, chemical reagents for medical or veterinary purposes for the detection and monitoring of disease states including cardiac, DOA, stroke, metabolic, cancer, diabetes, fertility, thyroid and DNA arrays; clinical diagnostic preparations, for medical or veterinary use; clinical diagnostic reagents for in vivo use for medical or veterinary purposes; diagnostic scanning agents for in vivo use for medical or veterinary purposes; diagnostic testing materials for medical use in the detection and monitoring of disease states in vitro, namely, chemical reagents for medical or veterinary purposes for the detection and monitoring of disease states including cardiac, DOA, stroke, metabolic, cancer, diabetes, fertility, thyroid and DNA arrays; medical diagnostic proteins, namely, protein arrays for medical diagnostic purposes featuring antibodies and antigens used for medical detection of disease states in vitro; chemical reagents, namely, chemical reagents for detection and monitoring of disease states in vitro | ACTIVE | — |
| 009 | Downloadable computer software for use in conjunction with in vitro diagnostic testing apparatus, namely, software for controlling medical and clinical sample processing, sample result reporting and test apparatus system robotics; computer hardware for or relating to the analysis, monitoring, research and/or reporting of clinical data; downloadable computer programs for use in conjunction with in vitro diagnostic testing apparatus for controlling medical and clinical sample processing and sample result reporting; computer systems, namely, computer hardware and downloadable software for use in conjunction with in vitro diagnostic testing apparatus for controlling medical and clinical sample processing and sample result reporting; computer systems for use in conjunction with in vitro diagnostic testing apparatus, namely, downloadable computer software and hardware for controlling medical and clinical sample processing; downloadable computer databases and computer databases recorded on computer media for use in connection with in vitro diagnostic testing apparatus, namely, downloadable electronic data files featuring medical diagnostic sample results; scientific and optical apparatus and instruments, namely, a benchtop analytical system composed of barcode scanner and associated software for reading barcodes, a chemiluminescent detection system in the nature of instruments for measuring chemiluminescence, a temperature controlled incubator for laboratory use, and an electronic reagent and patient sample dispenser, suitable for protein and DNA arrays for or relating to the analysis, monitoring, research and/or reporting of clinical data, for use in vitro diagnostic testing procedures for clinical, veterinary, food and toxicological analysis; clinical analyzers not for medical and veterinary use, namely, acidity analyzers, liquid analyzers, residual gas analyzers for use in vitro diagnostic testing procedures and for use in measuring blood proteins, antibodies, enzymes, immunoglobulins, hormones and drugs for laboratory use; light detectors for use in vitro diagnostic testing procedures, namely, a chemiluminescence detection system not for medical purposes; parts and fittings for all the aforesaid goods, namely, replacement parts and fittings | ACTIVE | — |
| 010 | Medical apparatus and instruments for medical use, namely, for use in vitro diagnostic testing procedures to detect and diagnose drug residues used in immunoassay procedures and for use in measuring blood proteins, antibodies, enzymes, immunoglobulins and hormones; diagnostic apparatus and instruments for medical use, namely, for use in vitro diagnostic testing procedures to detect and diagnose drug residues used in immunoassay procedures and for use in measuring blood proteins, antibodies, enzymes, immunoglobulins, hormones and drugs; diagnostic imaging apparatus for medical use, namely, electromechanical diagnostic analyser utilizing a chemiluminescent detection system for use in in vitro diagnostic testing procedures and for use in measuring blood proteins, antibodies, enzymes, immunoglobulins, hormones and drugs; medical diagnostic testing apparatus and instruments for use in immunoassay procedures, namely, for use in the measurement of antibodies, immunoglobulins, hormones and drugs representing various drug classes; light detectors for use in vitro diagnostic testing procedures, namely, a chemiluminescence detection system for medical purposes; clinical analyzers for medical and veterinary use, namely, acidity analyzers, liquid analyzers, residual gas analyzers for use in vitro diagnostic testing procedures and for use in measuring blood proteins, antibodies, enzymes, immunoglobulins, hormones and drugs | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Randox Laboratories Ltd
- Other trademarks owned by Randox Laboratories Ltd
- Other trademarks owned by Randox Laboratories Ltd
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Similar marks named RANDOX DISCOVERY
- Prosecution event R.PR explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 24, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 22, 2020 | ERTI | TEAS RESPONSE TO PETITION INQUIRY LETTER | — |
| Oct 21, 2020 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Oct 20, 2020 | APET | ASSIGNED TO PETITION STAFF | — |
| Oct 14, 2020 | TPEX | SOU EXTENSION RECEIVED WITH TEAS PETITION | — |
| Oct 13, 2020 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 12, 2020 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 1, 2020 | TPAD | TEAS PETITION TO AMEND BASIS RECEIVED | — |
| Mar 10, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 14, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 14, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 25, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 6, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 5, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 5, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 5, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 5, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 22, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 22, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 15, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 15, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 15, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 15, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 8, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 19, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 11, 2019 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Mar 11, 2019 | ALIE | ASSIGNED TO LIE | — |
| Mar 6, 2019 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Mar 2, 2019 | NWAP | NEW APPLICATION ENTERED | — |